secwatch.observer — SEC 8-K summary
======================================

Issuer:     INOVIO PHARMACEUTICALS, INC. (INO)
CIK:        0001055726
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001193125-24-137228
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inovio Q1 net loss narrows to $30.5M; BLA for INO-3107 on track for H2 2024
---------------------------------------------------------------------------

- BLA submission for INO-3107 (recurrent respiratory papillomatosis) on track for H2 2024 under accelerated approval pathway.
- Phase 3 trial of INO-3112 + LOQTORZI for HPV-related throat cancer advancing; FDA feedback received.
- Net loss $30.5M ($1.31/sh) vs $40.6M ($1.89/sh) in Q1 2023; R&D expenses fell to $20.9M.
- Cash & equivalents $105.6M at Mar 31, 2024; April offering raised net ~$33.2M; cash runway into Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1055726/000119312524137228/0001193125-24-137228-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1055726/000119312524137228/d774987d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-137228

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer